CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vaxart Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vaxart Inc
170 Harbor Way, Suite 300
Phone: (650) 550-3500p:650 550-3500 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: VXRTVXRT
Business Summary
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Michael J.Finney 65 3/18/2024 2/13/2018
President, Chief Executive Officer, Director StevenLo 56 3/18/2024 3/18/2024
Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer Phillip E.Lee 36 12/15/2022 12/15/2022
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Vaxart, Inc. 600 Townsend St,120E San Francisco CA United States
Biota Holdings Ltd Notting Hill, U 10 585 Blackburn Rd Melbourne VIC Australia
Biota Holdings Limited (ADR) Unit 10, 585 Blackburn Road Notting Hill VIC Australia

Business Names
Business Name
Anaconda Pharma
AVIR
Biota Holdings Pty, Ltd.
6 additional Business Names available in full report.

General Information
Number of Employees: 109 (As of 12/31/2023)
Outstanding Shares: 173,861,684 (As of 3/7/2024)
Shareholders: 2,264
Stock Exchange: NASD
Federal Tax Id: 591212264
Fax Number: (650) 871-8580
Email Address: invinf@nabi.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024